Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good afternoon, Ek,
The quote below is from your reply to my most recent post.
"So which is it immunotherapies are good (now that Voova said it, this seems to be OK).....but when I pointed immunotherapies out, they were ridiculed and dismissed as too expensive and too difficult.......talk about hypocrites."
Are you asking me a question? What specifically are you referring to? Where has voova stated that those therapies are "good"? Who are the hypocrites? Am I meant to be one of them?
I am more than a little puzzled about the stance you are taking. If you have a problem with anything another poster has said, please take it up with them directly!
HappyBee
Good morning (afternoon), zzaatt,
Thank you for your excellent post. I always appreciate your views because rather than being narrow-minded and repetitive, they display an understanding of the wider issues at stake with this particular investment.
I am in full agreement with you, voova and others that competition should not be regarded as something negative, but as something to welcome with little hesitation. As you so rightly state in the quote below, the world needs effective remedies for more than just a handful of diseases.
"Unhappily, the human body is subject to many maladies, and these very new
approaches (esp. immuno-therapies, such as CAR-T, and stem cells such
as Pluristem) have a broad range of diseases to attack. This will be done by
a multitude of biotechs and BPs, there's plenty to do for many."
I end with a quote from Gary (post #11070) that mirrors some of my sentiments.
"if the science is sound, I believe that success will come in time"(very well said, Gary!).
Best wishes,
HappyBee
PS Thank you for the interesting links, FDA.
EK, we appear to have a serious communication problem.
You claimed in your earlier post that Pluristem had done nothing (hip replacement) since 2011. This is clearly not the case. I googled "Pluristem hip replacement". A lot of information appeared and I chose three links that referred to Pluristem's activities since 2011. In your most recent reply you only refer to one link. What about the link from the Charite in Berlin, the information is fairly recent, late 2017. You say nothing about that. I find that rather telling. Are you saying that phases I/II/III of clinical trials are a work of fiction?
HB
EK, you are saying, "Well, for one the hip replacement data was from 2011...and they made promises they missed, 7 years later and ZIPPO has been done with it." Are you sure?
I have copied a few links for you (I quickly googled "Pluristem hip replacement"), in chronological order, that seem to paint an altogether different picture. In one of the links you will find a reference to refined surgical procedures.
https://seekingalpha.com/article/820631-pluristem-therapeutics-shoots-from-the-hip-moving-toward-the-sports-medicine-and-muscle-regeneration-markets
https://ryortho.com/breaking/pluristem-trial-of-plx-pad-cells-for-femoral-neck-fracture/
https://gutes-tun.charite.de/en/metas/en_meldung/artikel/detail/regenerative_zelltherapie_nach_hueftfrakturen/
If the share price drops by 20% I will not sell. For some investors it may indeed present another buying opportunity.
HappyBee
The week has started on a very interesting note.
When I looked at the Yogi quote in zzaatt's post, I assumed that it meant Yogi Bear, but was not sure. It turns out the quote was attributed to someone I am not familiar with at all. However reading other quotes that are attributed to Yogi, he appears to have been someone full of wisdom in a quirky sort of way.
I have also been reminded today as part of the investment challenge of a particular definition of insanity (personally I don't agree with this definition, sorry Herr Einstein, I wonder what Yogi would have said about that).
What has really surprised me, however, is EK saying something positive about Pluristem.
"The past good results...seen it before multiple times". I see this as a reference to previous early stage clinical trials. Now that Pluristem have moved on to late stage trials it is perfectly reasonable, I think, for EK to say "this time I want proof". I am with you there, EK, and I am sure we will be provided with the expected information in due course as part of due regulatory process being followed. Therefore I am at a bit of a loss with this final quote from EK's post "....and it seems there is none [proof] coming based upon their missed milestones." I thought that the FDA and EMA would play an important part in the regulatory approval process and not so-called "missed milestones" from the past. I cannot understand this and as you so poignantly put it, zzaatt, "because it's simply not indicated by reality".
HappyBee
Good evening zzaatt,
Your "simple consolidation" is spot on and very eloquent, a perfect summary. Thank you!
I find it reassuring that that there are likeminded posters and I am not alone with the way I see things.
Thank you, Saud, for your nice response.
Best wishes,
HappyBee
Hi Melon,
Thank you for your views and the link. I think what you are saying regarding the possible early approval makes a lot of sense and when you read further on the EMA website I am fairly hopeful that early/conditional may be forthcoming in due course. We obviously are not privy to inside information, but from early stage clinical trials (carried out by reputable research teams) we already know that the treatment was already showing some promise. Regarding the late stage CLI trial you may also recall this quote from a recent article in the Jerusalem Post.
"Prof. Nikol, the principal investigator of this Phase III trial, told The Jerusalem Post, “We don’t know for sure that it will be effective, but we already have hints it may work.”
http://www.jpost.com/HEALTH-SCIENCE/Smart-cells-that-heal-542584
My impression of the adaptive pathway is one of regular dialogue between all parties involved and given that Pluristem's therapy was chosen for the adaptive pathway is rather telling in itself. There appears to be a great willingness by regulatory bodies to help patient groups with unmet medical needs. Taking into consideration information currently in the public domain it almost seems to be a question of when regulatory approval will be forthcoming rather than if. Given the currently very limited treatment options for CLI patients, from a personal point of view, I would hope that this treatment would be available sooner rather than later. As shareholders we may "suffer" the ups and downs of a fluctuating share price, but this cannot be compared to what those patient groups have to endure.
As for the "inconceivable" question (very nice film reference!), I think that perceived organised efforts (within legal means) to suppress the share price are totally conceivable in my opinion. I am not entirely surprised given the innovative nature of Pluristem's therapies, that their work has not yet made a big impact on public awareness.
Please find below another link from the EMA with useful information. Have a look at the sidebar options. You will find a lot of interesting information.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000601.jsp&mid=WC0b01ac05807d58ce
You may, of course, have already seen this.
Best wishes,
HappyBee
It was a genuine mistake, EK!
Have a good weekend,
HappyBee
Apologies, EK, I always get the two of you mixed up. The post was indeed addressed to you. HB
Superman! [ ] ~~
Scott, I have news for you. I am not selling my shares. I'm sure Spidey and D will understand. Since I'm in profit with my shares I have nothing to complain about. I like Pluristem as a company.
As Allo put it so brilliantly a while back I suggest you "put that in your pipe and smoke it".
Have a good weekend,
HappyBee
Hi Saud,
Many thanks for adding to my "investment vocabulary" today! Very much appreciated!
Best wishes,
HappyBee
From Investopedia.
"DEFINITION of 'Dead Money'
A slang term for money invested in a security with minor hopes of appreciation or earning a return. The stock may also be referred as dead money by analysts [my emphasis], as a warning to investors who might purchase the shares."
"What is an 'Investment Analyst'
An investment analyst is a financial professional with expertise in evaluating financial and investment information, typically for the purpose of making buy, sell and hold recommendations for securities. Brokerage firms, investment advisors and mutual fund companies hire investment analysts to prepare investment research for multiple purposes. The most prestigious certification an investment analyst can receive is the Chartered Financial Analyst (CFA) [my emphasis] designation."
From the most recent Edison report, 28 February 2018 (thank you FDA/Allo and n3m3sis).
"Valuation: Increased to $208m or $1.89/basic share
We have slightly increased our valuation to $208m (from $202m) or $1.89 per basic share. This is largely driven by advancing our NPVs and a delay in the cost of the IC program, offset by an increase in our expected SG&A run rate. We expect to update our valuation with the completion of the Phase II IC trial in fiscal Q418. We forecast that the company will require $50m in additional financing before profitability in 2020."
Authors: Maxim Jacobs, Chartered Financial Analyst (CFA) [my emphasis], Director of Healthcare and Research North America, Edison Investment Research and Dr Nathaniel Calloway, PHD Chemistry, Financial Analyst, Edison Investment Research.
Based on the information currently available I do not believe Pluristem is "DEAD MONEY". I am also in agreement with Spideyboy regarding the share price.
HappyBee
Thank you, Melon!
Mr Blue,
I would like to ask you respectfully to give details of the post you are referring to (in your post #10923).
May I also remind you that no_ur_stox provided the link and I took the liberty to click on it and have a further look. Is that not allowed? I suspect that I am not the only person who looked at the link in further detail. Did you?
With specific reference to my earlier post today, if you look at the detailed information on the website it does show that a great number of trades were carried out in one week (by a number of entities) and when you calculate an average number of shares per trade you arrive at figures that may lend themselves to what Allo has suggested. That's all. I would rather you told us about your interpretation of the information from the link than make insinuations based on an alleged similarity in wording in some previous post.
I would also like to encourage you to read my posts very carefully. You may detect the presence of words like "may", "possibly", etc. I do not make claims I cannot support.
HappyBee
PS Sincere apologies to Melon and everyone else for "disturbing the peace", but I am really fed up with continually being on the receiving end of some, in my opinion, serious nonsense (insinuated and otherwise) about myself.
Hi Allo, when I looked at the information I did think that it may support what you have been telling us about.
Best wishes,
HappyBee
Apologies, I forgot to include the following information in my previous post.
I selected 12/18/2017 as the date ("weekly report") and the column referred to in my previous post came up.
HB
Good morning no_ur_stox,
Thank you for providing the link.
I have clicked on the link and I clicked through, entered Pluristem Therapeutics (issue) and then clicked on NMS Tier 2 (not sure what that means). You also have a date range option you can click on. Pluristem does appear. This is just one example. Please see below.
Symbol
Description
Total Shares
Total Trades
Last Updated
Details
PSTI Pluristem Therapeutics, Inc. - Common Stock 96,543 491 01/22/2018
At the end of that row you have the option to click on "details" and a document appears with quite detailed information.
I would be grateful, if anybody could enlighten me as to what it all means as I am not familiar with certain specialist aspects of the stock market, for example, "dark pools".
Best wishes,
HappyBee
Good morning (afternoon),
Thank you, Allo, for informing us about the latest developments, as always it is much appreciated. It would be very nice indeed if your predictions came true.
Zzaatt, I could not agree more with your views, you have put it very well.
Markets do seem to be somewhat unpredictable at times. However, what matters most in the long run is that the therapies prove themselves as part of the research as indicated in this quote from your post.
"Every new piece of data, from diverse medical
and scientific sources adds to the probability of this treatment
proving itself to be effective (and we just got one more !)"
Best wishes,
HappyBee
Good morning (afternoon) zzaatt,
I am very pleased that you are having such an excellent start to the week and are busy "empire building". I agree at the current price you may be (actually, change that to "are") getting very good value for money.
I did see your response yesterday, it is archived! Now that was quite something! I haven't responded yet, because I need to find a way to write a reply that at least has a chance to stand the test of time. It may appear in dribs and drabs.
Regarding the Investment Challenge. I understand that the "TQ" of your views expressed in writing may be somewhat limited, but never underestimate the potential of your "benevolent saintliness" [ :) ]!! (like the stock market it can rise and fall, I think).
I thought I repost a quote from you (slightly edited!), because it is rather nice and may interest others.
"I do want to emphasize that I really appreciate the posts by a number of
people (I wont list them since I'm likely to leave out somebody), they're
extending and adding to my DD and add perspective to the ongoing adventure of investing
in this very exciting technology (BUT, I do want to mention FDA/allo, who's
enthusiasm and research is a good antodote to .......). "
Enjoy the rest of the day.
Best wishes,
HappyBee
PS Thank you for the links, Allo, they were very interesting.
Good afternoon,
EK, I cannot speak for others, but I do remember seeing some critical views/questions expressed here by some of us who have a more positive outlook. Not all of us have invested in this company for 10 years. Perhaps you should not be further disappointed, if other members of the board do not share your views or do not care to listen or may not even read your posts. As long as they are content with their investment that is all that counts for them and that includes me. I cannot see anything wrong with being amused by another poster's humorous response (referencing excessive laughter involving parts of the anatomy x many, many times).
Mr Blue, you are completely wrong, once and for all, I am not Allo, I do not have an agenda!! As far as Pluristem are concerned I own a substantial number of shares and currently I am slightly in profit (I have bought at different price points). I have previously stated that I consider Pluristem to be high risk and accordingly I will be watching any developments very closely. I take it one step at a time.
I hope I have made my position clear. As for the company Saud has recommended, I will still need to learn more about it and will do so once I finish writing this response.
I have nothing further to add.
HappyBee
To EK,
I do not want to get into any arguments, but I do not think your reference to an "all is well crowd" is a fair assessment of part of the board. What would you say if I referred to a select group here (including you) as the "all is awful crowd"? It is all a matter of context. I will be frank, but personally I cannot understand why anyone would invest in a company that they consider to be utterly useless (my impression!). Management is awful, board of directors is awful, etc., etc. with hardly anything postive to say, day after day. Of course, everyone is entitled to their own opinions about the company (!). There should be plenty of room here to accommodate differing views, but having been at the receiving end of some rather unpleasant insinuations and name calling (this is not specifically directed at you) from a select group I can understand when someone snaps and makes their views known in no uncertain terms.
You may think that individuals here are siding with others against you, but what about a right to reply. Just because someone's opinion is different does not mean they are an "enemy". I do not expect others to see things the way I do, but I will show solidarity when I choose to. That is my prerogative.
HappyBee
Hi Saud,
I agree, we do want them to succeed. I just spent some time looking at the Brainstorm website. I found it very easy to follow, very detailed clinical trial information. This is definitely a company worth looking into. They seem to operate in a different niche compared to Pluristem. Did you notice the recent announcement of Dr Anthony Polverino (Amgen, Kite Pharma connection) joining the the board? I will spend some more time learning about this company and may even consider a reshuffle of my share portfolio (I won't touch my Pluristem shares!). Thank you!
Have a good weekend,
HappyBee
Thank you for the link, Saud. I have watched it and found it very interesting (especially what he said about Big Pharma). I may have a further look at some of the other videos in the sidebar when time allows.
EK, you are not the only one not having received answers to questions asked on this board. My view is don't take it too seriously and perhaps you may find answers elsewhere (as suggested by DG). I recall that you told us last week that your wife's father is a doctor. Perhaps he could point you in the right direction (re: male/female survival rate).
I had a similar question to yours a little while ago regarding the perceived survival rate of female and male primates in the previous ARS trial. I even went one further and asked whether the relatively low numbers of the study group were sufficient to point to a difference in survival rates between the sexes. Not being a scientist myself, therefore falling into the category of "know- nothings", the relatively small trial size did make me wonder though whether this question was appropriate at that point in time. I did not receive an answer to my question on this board, but rather than fret about it I made my own enquiries. I will not go into too much detail here, but it seems I was not too far off the mark with my suspicions (after consulting someone with experience in statistics and experimental design). I understand now that it is a very complex area. The pivotal trial will hopefully provide more information.
When you buy shares you do not need to be an industry expert to do so. What matters is that you have the financial resources to purchase them. I therefore assume that an anonymous message board consists of people from a wide variety of backgrounds. I have found it helpful participating on this board, asking questions, being alerted to news, etc. I think that sometimes an opinion can be just as interesting as an expert analysis. When I have posted I have done so in good faith and never in a renumerated capacity. Even though I have arguably been treated with suspicion and with respect lacking on various occasions, for the time being I remain a member of this board. However, I cannot be expected to respond to every question and have all the answers.
HappyBee
Hi Spidey,
moving on swiftly from the sublime to the ridiculous. I am reminded of Mrs Doyle (from "Father Ted") offering cups of tea with her immortal words "go on, go on, go on, go on, go on....".
There's only so many cups of tea one can drink.
Best wishes,
HappyBee
PS The halo of sainthood is yours today!
It seems to me that some views could be analogous to moving in ever decreasing circles. This way of looking at things may blind an observer to Pluristem's true potential.
HappyBee
Scott,
"you're going to find that many of the truths we cling to depend greatly on our own point of view".
<> Obi-Wan Kenobi
Scott, I do take it as a compliment?
Best wishes,
HappyBee
PS We have already discussed the first paragraph, do pay attention, Scott!!
PPS Never be bamboozled by excessive numbers! HB
Message for zzaatt,
Never be unduly influenced by excessive laughter! Laughter is never a sign of expertise in the world of investment. It may be mistaken for such, but do not be fooled [!].
Best wishes and good luck with the investment challenge,
HappyBee
PS You are welcome and thanks for the laugh!!
That is an excellent point, Thunderforce! Why would the DoD even bother if Pluristem were as useless as some try to make out! HB
Hi Saud, I think you may be on to something here.Good night. HB[]
Good evening,
Regarding the Celgene spin-off, Celularity, certain posts caught my eye.
FDA, Melon, Saud, Straightshot and zzaatt (in alphabetical order) have made some very valid points in their posts and they speak for themselves. Given the complex scientific area of discussion, as a shareholder, not an industry expert (!), I can only comment in terms of my perception (to the "long-suffering readers" of my posts, therefore, please, take what I say with a "pinch of salt" and preferably read this in a relaxed setting with a glass of wine).
Melon made some interesting comments and also referred to hype. Hype is not a substitute for following due scientific and regulatory process when developing new therapies. Hype does not remove the uncertainty of future progress in the development of any new therapy. An impressive array of backers and a very healthy bank balance may help in terms of public perception and potential advantages n3m3sis referred to (direct quote: "Development can be accelerated a great deal if you have the funds to do it") but they do not, in themselves, provide a company with preferential treatment by the regulator and are not a guarantee for success. If valid, the science will eventually speak for itself.
I very much like FDA's quote, see below, because besides being witty it makes sense to me.
"Pluristem Is The Turtle And Celularity Is The HARE..IRI ! We All Know Who Won That Race ! YOU WILL SEE IN THE FUTURE IMO."
Saud's take on the business angle was very interesting, so I am reposting it, see below.
"their [Pluristem's] margins will be huge, and undercut everyone else on price, big advantage in the BUSINESS world, its all about margins! Zami figured that out a long time ago".
Straightshot to me seemed spot on in his post when he stated: "sure it is competition but more importantly it is validity... dare I say we are several years ahead of this new entity but we do need to get a successful trial under our belt to solidify our leading position... "
I also appreciated zzaatt providing a clear example of the implementation of CAR-T technology in the relevant setting and agree with his observation as quoted below.
"the applicability of the technology to literally millions of patients is simply not possible for CAR-T, at least not now, and maybe never!"
We just don't know yet what will transpire in the future and I agree with zzaatts's view that we may not even be comparing like with like.
I think overall perhaps we should not lose any further sleep [ :) ] over the Celgene spin-off.
HappyBee
PS Hi Allo, thank you for today's posts. I will look at the information in more detail later.
Good morning,
The success of a company will be determined by other factors than positive, neutral or negative views on a messageboard. The retail investor has the option to raise his/her grievances with the company directly or sell, if dissatisfied with the progress of their choice of investment.
Have a good week,
HB
PS Thank you, Allo, for posting some very interesting links yesterday. You do have the patience of a saint [ :) ].
Hi FDA and zzaatt,
thank you for your thoughts and links.
Taking into consideration the challenges any R and D company face I think with sufficient foresight and imagination even challenges perceived as unsurmountable should be able to be addressed. As the quote from zzaatt below shows therapies with utterly different MOA would hopefully be able to operate within a similar competitive market place. What is referred to in his clearly presented points 1- 4 is also my understanding.
"1. Pluristem's placental MSC approach is utterly different!
Its MOA is by remote action of secreted chemicals, by live cells
that have the full compliment of genetic code in place, and have
potentially multiple actions, all at the same time.
2. While the immuno approach simply cannot do the above (secrete multiple
therapeutic agents) placental stem cells could (and PLX-Immune showed that they do) impinge on
the cancer producing/sustaining pathways (different MOA, with similar therapeutic target)
3. Therefore, Pluristem's technology is more flexible, and has a
therapeutic space that is vastly greater than approaches that diddle (that's
not a technical term) the immune system to trigger/wake up the body's
immune response.
4. The two approaches will not knock each other out (nobody is DEAD!!!),
they may compete in some areas, for some particular pathology, but they are,
at least as far as MOA is concerned, different and complementary.
I believe that placental cells are the more general and
more broadly applicable agent. "
F|nally, I would like to share a quote.
"Order and simplification are the first steps toward the mastery of a subject"
<> Thomas Mann
I find this approach very helpful when dealing with all aspects of investment.
Best wishes,
HappyBee
Thank you for posting this, FDA. I had not see this before. Given the topics of discussion (potential competitors, patents) in the last few days I found this very []nteresting.
It is getting late where I live.
Good night.
HappyBee
I just want to say this. The current share price is not the whole story. I once owned shares in a company (biotech) over a period of a few years. The share price went up and down like a yoyo at times, quite extreme. I could not understand it, but I believed in what the company were doing. It was not plain sailing! If I had given up on the company when the price was very, very low, or sold in a panic (there were some negative news along the way) when the price edged up a bit higher, I would have seriously lost out. The company was eventually taken over and I almost tripled my investment (Gary recently presented some investment scenarios, and mine was not so much a percentage gain, but a dollar gain). I do sympathise that it is stressful and frustrating when the price is showing little progress or is on a downward spiral, but it is not the whole story. If anybody thinks I am naive, what can I say? When I post I do so in good faith. But I am certainly no fool when it comes to the investment challenge. (EOM)
Hi Spidey,
very nice to hear from you. I wondered whether you had "retired".
Thank you for your encouraging words.
I have some information that may interest our free subscribers. I have been reliably informed this week that free subscribers can use iHub's "Happy Hour" [ : ) ] every Friday from 4-5 p.m. EST to send Private Messages to other users (incl. those that moderate). It may help to get the investment challenge message (zz) across,
Best wishes,
HappyBee
jp, that would be very good! HB
Hi jp, I cannot think of any other company, but FDA may know.
Regards,
HB